Provider Briefing: Cefprozil Supply in 2026

Cefprozil, a second-generation cephalosporin widely prescribed for upper and lower respiratory tract infections, otitis media, sinusitis, and skin infections, has experienced intermittent supply disruptions that continue to affect patient access. This briefing provides prescribers with a current assessment of Cefprozil availability, practical prescribing considerations, and tools to help your patients fill their prescriptions.

Current Shortage Status and Timeline

As of Q1 2026, Cefprozil is not listed on the FDA's official drug shortage database. However, anecdotal reports and pharmacy-level data indicate ongoing spot shortages, particularly affecting:

• Oral suspension formulations (125 mg/5 mL and 250 mg/5 mL) — fewer manufacturers produce the liquid form, making it more vulnerable to disruption
• Certain geographic regions where distributor allocation limits reduce available inventory
• Peak respiratory season (October through March), when demand for oral antibiotics surges

The supply situation has been an intermittent issue for the past several years. The brand-name product (Cefzil, Bristol-Myers Squibb) was discontinued, and the generic market is serviced by a limited number of manufacturers including Lupin, Sandoz, Aurobindo, and Teva. This concentration of production means any single-manufacturer disruption can have outsized effects on availability.

Prescribing Implications

The availability constraints around Cefprozil have several practical implications for prescribers:

Verify Availability Before Prescribing

Consider checking pharmacy availability before sending a Cefprozil prescription electronically. Tools like Medfinder for Providers allow you to verify real-time stock at pharmacies near your patient, reducing the likelihood of a patient arriving at a pharmacy only to find the medication is unavailable.

Consider the Formulation

Tablet formulations (250 mg and 500 mg) have been more consistently available than the oral suspension. For patients who can swallow tablets, prescribing the tablet form may reduce fill failures. For pediatric patients or adults who need the liquid form, be prepared with an alternative if the suspension is unavailable.

Proactive Alternative Planning

Given the potential for fill failures, consider noting an alternative antibiotic on the prescription or in the patient's chart. This allows the patient to quickly contact your office for a new prescription rather than waiting for a callback. Evidence-based alternatives include:

• Cefuroxime (Ceftin) — second-generation cephalosporin with comparable spectrum and indications
• Cefdinir — third-generation cephalosporin; particularly well-suited for pediatric otitis media and sinusitis
• Cefpodoxime — third-generation cephalosporin; useful for respiratory and urinary tract infections
• Amoxicillin-Clavulanate — first-line alternative for most Cefprozil indications; widely available and cost-effective

Availability Picture Across Pharmacy Types

Pharmacy type significantly affects Cefprozil availability:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Subject to centralized distribution and allocation limits. May frequently be out of stock during peak season.
• Independent pharmacies: Often source from multiple wholesalers and may have access to stock when chains do not. Worth recommending to patients as a first alternative.
• Compounding pharmacies: Can prepare Cefprozil suspension from bulk powder if commercial product is unavailable. Requires verification of quality and appropriate formulation.
• Mail-order pharmacies: Larger centralized inventories may have better availability for non-urgent prescriptions.

Cost and Access Considerations

Cost remains a factor in patient adherence, particularly for uninsured or underinsured patients:

• Retail cash price: $60–$120 for a standard 10-day course of 500 mg tablets
• With discount programs: $24–$30 via GoodRx, SingleCare, or similar services
• Insurance coverage: Generic Cefprozil is typically covered as Tier 1 or Tier 2; copays usually $5–$15
• Suspension pricing: $13–$25 depending on strength and volume
• Patient assistance: No manufacturer-specific PAP exists for Cefprozil. General programs (NeedyMeds, RxAssist) may assist qualifying patients

For patients struggling with cost, direct them to our guide on saving money on Cefprozil, or use our provider-focused savings resource at helping patients save on Cefprozil.

Tools and Resources for Providers

Several tools can streamline the process of ensuring patients get their Cefprozil prescriptions filled:

Medfinder for Providers

Medfinder offers real-time pharmacy availability data. You or your staff can check which pharmacies in your patient's area have Cefprozil in stock before prescribing, reducing fill failures and patient frustration.

FDA Drug Shortage Database

Monitor the FDA drug shortage database for any official updates on Cefprozil supply status. While Cefprozil is not currently listed, status can change.

ASHP Drug Shortage Resource Center

The American Society of Health-System Pharmacists (ASHP) maintains a drug shortage database that may provide additional granularity on cephalosporin supply issues.

Looking Ahead

The fundamental dynamics driving Cefprozil supply challenges — limited generic manufacturers, global API supply chain vulnerabilities, and low profit margins for generic antibiotics — are not expected to change significantly in the near term. Prescribers should anticipate continued intermittent availability issues and plan accordingly.

Key strategies include:

• Maintaining familiarity with evidence-based alternatives
• Using real-time availability tools like Medfinder to guide prescribing decisions
• Educating patients about the possibility of fill delays and having a backup plan ready
• Considering tablet formulations over suspension when clinically appropriate to improve fill success rates

Final Thoughts

Cefprozil remains an effective and well-tolerated antibiotic for common respiratory and skin infections. While supply disruptions continue to pose challenges, proactive prescribing strategies and real-time availability tools can significantly reduce the impact on your patients. By staying informed about the current supply landscape and having alternatives ready, you can ensure that a pharmacy stock issue doesn't delay the care your patients need.

For more provider resources, visit Medfinder for Providers or read our companion guide on how to help your patients find Cefprozil in stock.